Medical Congress Specialist, Oncology

Overview

The Medical Congress Specialist, Oncology will play a critical role in ensuring that US Medical Affairs congress and sponsorship related activities are executed seamlessly. This individual will partner across the hematology and solid tumor disease areas in supporting US Medical congresses and scientific meetings with an external scientific exchange role (e.g. congresses, scientific booths). This role will ensure alignment across US Medical Affairs cross divisionally while driving medical execution on all pre-, peri-, and post- congress activities. The coordinator will liaise closely with the specific Business Owner, US Congress Lead, Scientific Communications lead, Regional Directors, Medical Directors, Medical Affairs Operations, home office personnel and agency partners to ensure successful congress planning and execution. They will support the Business Owner for sponsorships or ancillary congress activity as well as align content with Legal and Regulatory colleagues as needed. The coordinator will also maintain supporting documentation and records for audit readiness as well as capture all applicable metrics per project to allow a view into value and impact of each activity.

Responsibilities

• Devise a system for tracking medical affairs congress and sponsorship related activities to include, but not limited to the costs for sponsorships, required meeting space and/or securing venue, Audio/Visual needs, AC requirements, catering, Transfer of Value (TOV) capture and related EE/HCP sign-in sheets (as applicable), as well as time required from start to finish of each project.
• Establish a method of tracking Stemline assets used during congresses, sponsorships, and ancillary regional meetings, such as tabletop displays, pull-up banners, QR displays, etc., that can be pulled into a status and/or inventory report for the Scientific Communications Lead.
• Coordinate Sunshine Reporting with our internal partner including coordination with compliance partners for vendor Transfer of Value (TOV) training when applicable
• Manage ancillary congress, regional meetings, and sponsorship support requests for US Medical Affairs
• Facilitate recurring medical congress planning team calls as well as separate regional meeting planning calls with relevant team members
• Liaise with Scientific Communications to secure timely review and approval of medical booth content for congresses and sponsorships to ensure compliance with applicable local regulations and legal / regulatory guidance
• Collaborate with medical affairs leadership, commercial colleagues, and external vendors to to finalize and communicate HCP scientific exchange at medical congresses
• Provide onsite support as needed at various congresses as determined by Medical Affairs leadership
• Consider budget and finance reconciliations for Medical Affairs congress and sponsorship activities in alignment with medical affairs budget lead
• Cultivate positive relationships with internal, cross-functional colleagues and external vendor partners involved in scientific meeting congress and sponsorship activities
• Prioritize tasks, and organize and manage multiple projects
• Demonstrate ability to take initiative and consistently deliver high-quality, patient centric solutions in a timely fashion
• Facilitate post-congress debriefs and drive determination of return on investment for congresses by capturing and reporting on congress and sponsorship metrics related to overall impact, EE/HCPs engaged, insights gathered, and financial spend vs return on investment

Qualifications

• A minimum of a BA/BS required. Advanced medical and/or scientific degree is preferred
• Generally, 5-8 years' experience with project management in pharmaceutical industry, ideally including both experience leading congresses and experience in oncology
• Stellar record of being successful in a fast-paced, dynamic environment
• Proven ability to establish and maintain cross-functional relationships with a wide range of internal and external stakeholders
• Capability to work independently or in a team structure
• Demonstrated agility and ability to effectively work within new structures, processes, requirements, or cultures.
• Teamwork is a mandatory requirement; excellent collaboration, presentation, and communication skills (both written and oral) required.
• Strong organizational skills, attention to detail, ability to prioritize and meet deadlines.
• Critical thinking skills with unique problem-solving abilities for new and novel obstacles
• Demonstrated ability to plan budget and manage resources effectively

Remote Position with Travel up to 25% as needed

Base Salary Range of $105,000-$175,000. Menarini Stemline offers generous compensation and benefits packages, including Short- Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions

#LinkedIn

ABOUT US:

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group's headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini's oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini's commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB's CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient's therapeutic journey.

In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company's development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business.